Better outcomes require tailored strategies
The past 15 years has seen the advent of many new classes of antidiabetic agents. We now have biguanides, sulfonylureas, thiazolidinediones, dipeptidyl-peptidase IV inhibitors, glucagon-like peptide 1 receptor agonists, a variety of insulins and α-glucosidase inhibitors. This has resulted in a surfeit of choice, but has also increased the complexity of decision making as there is no simple algorithm for escalation of treatment that is optimal for all patients.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
I am the President of the Australian Diabetes Society and a member of the Australian Government’s Diabetes Advisory Group for the Diabetes Care Project.